Denis, Fabrice

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Denis, F., Basch, E., Septans, A.-L., Bennouna, J., Urban, T., Dueck, A. C., & Letellier, C. (2019) · JAMA

Cancer survivorship and careLung Cancer Diagnosis and Treatment

Cited by 549

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline

Di Maio, M., Basch, E., Denis, F., Fallowfield, L. J., Ganz, P. A., Howell, D., Kowalski, C., Perrone, F., Stover, A. M., Sundaresan, P., et al. (2022) · Annals of Oncology

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 509

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients

Denis, F., Lethrosne, C., Pourel, N., Molinier, O., Pointreau, Y., Domont, J., Bourgeois, H., Senellart, H., Trémolières, P., Lizée, T., et al. (2017) · JNCI: Journal of the National Cancer Institute

Lung Cancer Diagnosis and TreatmentCancer survivorship and care

Cited by 482